![](https://medcitynews.com/wp-content/uploads/sites/7/2017/06/GettyImages-684062466.jpg)
FDA approves Pfizer’s Vyndaqel, Vyndamax for cardiomyopathy in rare protein disorder
An analyst wrote that the drug's high price tag of $225,000 could limit its uptake in ATTR-CM, but it could become competitive with Alnylam's Onpattro.
An analyst wrote that the drug's high price tag of $225,000 could limit its uptake in ATTR-CM, but it could become competitive with Alnylam's Onpattro.